Veracyte Inc (Veracyte) is a molecular diagnostics company that uses genomic technology to resolve diagnostic ambiguity. The company’s pipeline products include Afirma thyroid FNA analysis for the diagnosis of thyroid cancer based on its proprietary afirma gene expression classifier. It also provides percepta bronchial genomic classifier as an assay to evaluate patients with lung nodules that are suspected of cancer. Veracyte offers genomic testing to other areas of substantial clinical need with diagnostic ambiguity. The company markets its afirma solutions through its sales force across the US. It also commercializes its products in Brazil. Veracyte is headquartered in South San Francisco, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Veracyte Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Veracyte Inc Company Overview
- Veracyte Inc Company Snapshot
- Veracyte Inc Pipeline Products and Ongoing Clinical Trials Overview
- Veracyte Inc - Pipeline Analysis Overview
- Veracyte Inc - Key Facts
- Veracyte Inc - Major Products and Services
- Veracyte Inc Pipeline Products by Development Stage
- Veracyte Inc Ongoing Clinical Trials by Trial Status
- Veracyte Inc Pipeline Products Overview
- Afirma - Risk of Recurrence
- Afirma - Risk of Recurrence Product Overview
- Afirma - Thyroid Cancer Staging/ Prognosis Test
- Afirma - Thyroid Cancer Staging/ Prognosis Test Product Overview
- Afirma Xpression Atlas - Pulmonology
- Afirma Xpression Atlas - Pulmonology Product Overview
- BronchoGen Test
- BronchoGen Test Product Overview
- Comprehensive Genomic Profiling Test
- Comprehensive Genomic Profiling Test Product Overview
- Decipher Prostate Biopsy
- Decipher Prostate Biopsy Product Overview
- Decipher Prostate Biopsy Clinical Trial
- Decipher Prostate RP Assay
- Decipher Prostate RP Assay Product Overview
- Decipher Prostate RP Assay Clinical Trial
- Diagnostic Assay - Renal Cancer
- Diagnostic Assay - Renal Cancer Product Overview
- Disease Diagnosis Device
- Disease Diagnosis Device Product Overview
- Envisia - Disease Progression Test
- Envisia - Disease Progression Test Product Overview
- Envisia - Rx Response Test
- Envisia - Rx Response Test Product Overview
- Envisia Genomic Classifier
- Envisia Genomic Classifier Product Overview
- Envisia Genomic Classifier Clinical Trial
- Envisia IVD Test
- Envisia IVD Test Product Overview
- nCounter Dx LymphMark Assay
- nCounter Dx LymphMark Assay Product Overview
- nCounter FLEX Analysis System - Idiopathic Pulmonary Fibrosis Test
- nCounter FLEX Analysis System - Idiopathic Pulmonary Fibrosis Test Product Overview
- Percepta Atlas
- Percepta Atlas Product Overview
- Percepta Nasal Swab Test
- Percepta Nasal Swab Test Product Overview
- Veracyte Inc - Key Competitors
- Veracyte Inc - Key Employees
- Veracyte Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Veracyte Inc, Recent Developments
- Jun 12, 2023: Veracyte Announces Afirma-Focused Abstracts to Be Presented at ENDO 2023
- Apr 27, 2023: Veracyte announces five abstracts providing molecular insights into prostate and other cancers to be presented at the 2023 ASCO Annual Meeting
- Mar 15, 2023: Veracyte Announces Three Abstracts to Be Presented at AACR Annual Meeting 2023
- Sep 13, 2022: Veracyte Names John Leite, Ph.D., as General Manager of Pulmonology & Market Access
- Sep 01, 2022: Veracyte to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
- Aug 11, 2022: Veracyte Appoints Eliav Barr, M.D., to Its Board of Directors
- Aug 02, 2022: Veracyte Announces Second Quarter 2022 Financial Results
- Jul 14, 2022: Veracyte to Release Second Quarter 2022 Financial Results on August 2 2022
- May 12, 2022: Veracyte announces that data for its genomic and Immuno-Oncology offerings will be highlighted at the 2022 ASCO Annual Meeting
- Feb 28, 2022: Veracyte Announces Fourth Quarter and Full-Year 2021 Financial Results
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- Veracyte Inc Pipeline Products and Ongoing Clinical Trials Overview
- Veracyte Inc Pipeline Products by Equipment Type
- Veracyte Inc Pipeline Products by Indication
- Veracyte Inc Ongoing Clinical Trials by Trial Status
- Veracyte Inc, Key Facts
- Veracyte Inc, Major Products and Services
- Veracyte Inc Number of Pipeline Products by Development Stage
- Veracyte Inc Pipeline Products Summary by Development Stage
- Veracyte Inc Ongoing Clinical Trials by Trial Status
- Veracyte Inc Ongoing Clinical Trials Summary
- Afirma - Risk of Recurrence - Product Status
- Afirma - Risk of Recurrence - Product Description
- Afirma - Thyroid Cancer Staging/ Prognosis Test - Product Status
- Afirma - Thyroid Cancer Staging/ Prognosis Test - Product Description
- Afirma Xpression Atlas - Pulmonology - Product Status
- Afirma Xpression Atlas - Pulmonology - Product Description
- BronchoGen Test - Product Status
- BronchoGen Test - Product Description
- Comprehensive Genomic Profiling Test - Product Status
- Comprehensive Genomic Profiling Test - Product Description
- Decipher Prostate Biopsy - Product Status
- Decipher Prostate Biopsy - Product Description
- Decipher Prostate Biopsy - A Validation Study on the Impact of Decipher Testing on Treatment Recommendations in African-american and Non-african American Men with Prostate Cancer (VANDAAM Study)
- Decipher Prostate Biopsy - Genomics in Michigan to Adjust Outcomes in Prostate Cancer (G-MAJOR): A Randomized Multi-center Study for Men with Newly Diagnosed Favorable Risk Prostate Cancer
- Decipher Prostate Biopsy - Study to Validate the Performance of Decipher Biopsy Genomic Classifier in Patients with Intermediate-risk Prostate Cancer
- Decipher Prostate RP Assay - Product Status
- Decipher Prostate RP Assay - Product Description
- Decipher Prostate RP Assay - Genomics in Michigan Impacting Observation or Radiation (G-MINOR)
- Diagnostic Assay - Renal Cancer - Product Status
- Diagnostic Assay - Renal Cancer - Product Description
- Disease Diagnosis Device - Product Status
- Disease Diagnosis Device - Product Description
- Envisia - Disease Progression Test - Product Status
- Envisia - Disease Progression Test - Product Description
- Envisia - Rx Response Test - Product Status
- Envisia - Rx Response Test - Product Description
- Envisia Genomic Classifier - Product Status
- Envisia Genomic Classifier - Product Description
- Envisia Genomic Classifier - Bronchial Sample Analysis for a Novel Genomic Test: BRAVE
- Envisia Genomic Classifier - CATALYST Study: A Clinical Utility Analysis of the BRAVE (Bronchial Sample Collection for A Novel Genomic Test) Registry Using the Envisia Genomic Classifier
- Envisia IVD Test - Product Status
- Envisia IVD Test - Product Description
- nCounter Dx LymphMark Assay - Product Status
- nCounter Dx LymphMark Assay - Product Description
- nCounter FLEX Analysis System - Idiopathic Pulmonary Fibrosis Test - Product Status
- nCounter FLEX Analysis System - Idiopathic Pulmonary Fibrosis Test - Product Description
- Percepta Atlas - Product Status
- Percepta Atlas - Product Description
- Percepta Nasal Swab Test - Product Status
- Percepta Nasal Swab Test - Product Description
- Veracyte Inc, Key Employees
- Veracyte Inc, Other Locations
- Veracyte Inc, Subsidiaries
- Glossary
- Veracyte Inc Pipeline Products by Equipment Type
- Veracyte Inc Pipeline Products by Development Stage
- Veracyte Inc Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Atara Biotherapeutics Inc
- GeneThera Inc
- Kerma Medical Products Inc
- Lifelines Neurodiagnostic Systems Inc
- Lineage Cell Therapeutics Inc
